Ardelyx Announces Departure of Board Member
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – ARDX
The recorded move for ARDX in the trading session of this news was +5.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Geoffrey Block, MD, is stepping down from the Board of Directors after nearly five years of service. Dr. Block currently serves as the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care.
“On behalf of our board and Ardelyx’s leadership team, we thank Geoff for his unwavering commitment and the instrumental role he played in helping guide and evolve Ardelyx from a developmental, clinical-stage biopharmaceutical company to an established commercial entity,” said David Mott, Chair of the Ardelyx Board of Directors. “It has been a pleasure working with Geoff, and I would personally like to thank him for his ongoing support.”
“I am very proud of this leadership team’s many accomplishments and am grateful for the opportunity to have served on the board of directors,” said Dr. Block. “Ardelyx is well-positioned for the future, following the U.S. FDA approval of the first-in-class phosphate absorption inhibitor XPHOZAH® (tenapanor) which is a new option for the many patients with chronic kidney disease on dialysis, a community I have dedicated my career to serving. The time is right for me step down from the board of directors as Ardelyx embarks on its next phase.”
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin has received approval for PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
